Aurora kinase A drives the evolution of resistance to third generation EGFR inhibitors in lung cancer

Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance. How tumors transition between drug responsiveness, tolerance and resistance, especially in the absence of pre-existing subclones, remains u...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Nat Med
Hlavní autoři: Shah, Khyati N., Bhatt, Roma, Rotow, Julia, Rohrberg, Julia, Olivas, Victor, Wang, Victoria E., Hemmati, Golzar, Martins, Maria M., Maynard, Ashley, Kuhn, Jonathan, Galeas, Jacqueline, Donnella, Hayley J., Kaushik, Swati, Ku, Angel, Dumont, Sophie, Krings, Gregor, Haringsma, Henry J., Robillard, Liliane, Simmons, Andrew D., Harding, Thomas C., McCormick, Frank, Goga, Andrei, Blakely, Collin M., Bivona, Trever G., Bandyopadhyay, Sourav
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324945/
https://ncbi.nlm.nih.gov/pubmed/30478424
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41591-018-0264-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky